Prion diseases in humans and other mammals are characterized by a conformational transition of the cellular prion protein (PrP C ) 5 into an aberrantly folded isoform, designated scrapie prion protein (PrP Sc ). PrP Sc can form amyloid plaques in the diseased brain and is the major constituent of infectious prions (for reviews, see Refs. [1] [2] [3] [4] . Propagation of PrP Sc is strictly dependent on the synthesis of PrP C by the host (5) and involves a direct interaction of the two conformers (6, 7) . Both mature PrP C and PrP Sc contain a glycosylphosphatidylinositol (GPI) anchor and two N-linked carbohydrate moieties of complex structure, indicating that the conversion takes place after trafficking of PrP C through the secretory pathway at the plasma membrane or within endocytic compartments (8 -12) . However, both post-translational modifications are not required for PrP Sc formation. Studies in prion-infected cultured cells and transgenic mice indicated that PrP C devoid of N-linked glycans still supports PrP Sc propagation and formation of infectious prions (13) . Similarly, transgenic mice expressing a secreted version of PrP C by deleting the C-terminal GPI anchor signal peptide (PrP⌬GPI) propagate infectious prions after infection (14, 15) .
Based on transgenic studies published by Prusiner and coworkers (6, 7), in 1991 John Hardy (16) 
Results

A neurotoxic mutation does not interfere with homodimerization of PrP
The formation of PrP C dimers was reported previously (17) (18) (19) , and the internal HD has been identified as a putative dimerization domain (21) . To address a possible role of PrP dimerization in the formation of a neurotoxic PrP conformer, we studied dimerization of PrP(AV3) in mouse neuroblastoma (N2a) cells. PrP(AV3) contains three alanine-to-valine changes within the HD (Fig. 1A) and causes early onset neurodegeneration upon expression in transgenic mice (22) .
To force formation of PrP dimers, we replaced serine 132 by cysteine in PrP(AV3) (Fig. 1A) . In case PrP dimerizes, an intermolecular disulfide bond can be formed that is stable in SDS buffer under nonreducing conditions (Fig. 1B) . This approach was successfully used to study dimerization of the transmembrane receptor ErbB-2/Her2 (23), the amyloid precursor protein (24) , and WTPrP C (19) . Indeed, Western blot analysis of transiently transfected N2a cells revealed that similarly to WTPrP C the neurotoxic PrP(AV3) mutant forms homodimers that disassemble in the presence of reducing agents, such as ␤-mercaptoethanol (ME) (Fig. 1C) . The ratio of monomeric/ dimeric PrP species was stable at various expression levels, indicating that dimer formation was not an artifact of PrP overexpression (Fig. 1D) .
PrP is characterized by a series of post-translational modifications. It is modified by two N-linked glycans of complex structure, a C-terminal GPI anchor, and an internal disulfide bond (for a review, see Ref. 25) . To study whether forced dimerization interferes with maturation and/or cellular trafficking, we performed an indirect immunofluorescence analysis of cells transiently transfected with our PrP constructs. The staining pattern did not reveal obvious differences between the PrP variants containing a cysteine or serine at position 132, indicating that disulfide bond-linked dimers of WTPrP C and PrP(AV3) are transported through the secretory pathway ( Fig.  2A, permeabilized) and are localized at the outer leaflet of the plasma membrane ( Fig. 2A, non-permeabilized) . To analyze the cell surface localization of PrP dimers in more detail, transfected cells were treated either with trypsin to remove extracellular domains of membrane-anchored proteins in general or with phosphatidylinositol-specific phospholipase C (PIPLC) to specifically liberate GPI-anchored proteins. As shown by Western blot analysis, trypsin treatment of live cells significantly reduced the signals of both PrP monomers and dimers in cell lysates, confirming that PrP dimers had been located at the plasma membrane (Fig. 2B) . The cytosolic protein GAPDH was not affected by trypsin, verifying that the protease only digested extracellular proteins (Fig. 2B) . Similarly, after incubation with PIPLC, monomeric as well as dimeric PrP was present in the cell culture media (Fig. 2C) , demonstrating that the PrP dimers were inserted in the plasma membrane via a GPI anchor. Another post-translational modification of PrP is the conversion of the two N-linked glycans into complex structures (11) . To evaluate the glycosylation status of PrP in detail, cell lysates were treated with endoglycosidase H (EndoH), which only cleaves high-mannose N-linked glycans, or peptide:N-glycosidase F (PNGaseF), which cleaves high-mannose, hybrid, and complex oligosaccharides from N-linked glycoproteins. Forced dimerization via the introduced cysteine residue did not interfere with complex glycosylation because the electrophoretic mobility of PrP was only increased after PNGaseF (Fig. 2D , left panel) but not after EndoH digestion (Fig. 2D, right panel) . Notably, the enzyme reaction buffer contains reducing agent. Thus, only monomeric PrP is seen in Western blot analysis after EndoH or PNGaseF digestion. If PrP dimers were modified with high-mannose glycans only, an additional band would appear in the EndoH-treated samples.
This analysis revealed that neurotoxic mutations in the hydrophobic domain do not interfere with the dimerization of PrP. In addition, our data indicated that an engineered intermolecular disulfide bond between the hydrophobic domains of two PrP molecules does not impair maturation and cellular trafficking. Like WTPrP C , covalently linked PrP dimers are complex glycosylated and anchored to the outer leaflet of the plasma membrane via a GPI anchor.
A neurotoxic PrP mutant forms heterodimers with WT PrP
C
To analyze whether the mutations in the HD might interfere with the formation of PrP(AV3)/WTPrP heterodimers, we inserted an HA epitope tag into WTPrP C and a V5 epitope tag into PrP(AV3). Both proteins contain a cysteine at position 132 to allow intermolecular disulfide bond formation (Fig. 3A) . N2a cells transiently coexpressing WTPrP-HA and PrP(AV3)-V5 were lysed and subjected to immunoprecipitation with anti-HA antibodies under nonreducing conditions. The immunopellet was then analyzed by Western blotting using anti-V5 antibodies. PrP(AV3)-V5 copurified with WTPrP-HA, indicative of the formation of PrP heterodimers (Fig. 3 , B and C). As a control, anti-HA immunoprecipitations were performed in lysates from cells that express either HA-tagged WTPrP C or V5-tagged PrP(AV3). In neither case was V5-positive PrP detected in the immunopellets.
The formation of disulfide bond-stabilized PrP homo-and heterodimers indicated that PrP C has an intrinsic propensity to at least transiently undergo homotypic interactions in the PrP dimerization inhibits prion formation secretory pathway of neuronal cells. To assess the dimerization under physiological conditions, we performed native immunoprecipitation assays with HA-and V5-tagged PrP constructs that did not include the Cys-132 mutation (Fig. 4A ). Cells were cotransfected with an HA-together with a V5-tagged PrP construct, and cell lysates were subjected to immunoprecipitation under native conditions with anti-HA antibodies. The resulting immunopellet was then analyzed by Western blotting using anti-V5 antibodies. Using this approach, we could verify the formation of homodimers of WTPrP C and PrP(AV3) under physiological conditions (Fig. 4B , wt-HA ϩ wt-V5 or AV3-HA ϩ AV3-V5). Moreover, we could also detect heterodimers formed between WTPrP C and PrP C (AV3) (Fig. 4B , wt-HA ϩ AV3-V5). In lysates prepared from cells that express only V5-or HA-tagged PrP, no specific signals were detectable in Western blot analysis, demonstrating the specificity of the assay.
Dimerization of PrP C blocks formation of PrP Sc
Encouraged by the finding that maturation and intracellular trafficking of covalently linked PrP dimers were comparable with those of native PrP C , we tested whether PrP dimers can be converted into PrP Sc . To this end, we used scrapie-infected mouse neuroblastoma (ScN2a) cells that propagate proteinase K (PK)-resistant PrP Sc and infectious mouse prions (26 -28) . After transient transfection with 3F4-tagged PrP constructs, the conversion of exogenous PrP is monitored by the appearance of 3F4-positive PK-resistant PrP species because endogenous mouse PrP Sc is not detected by the 3F4 antibody (29) . This conversion assay is illustrated in Fig. 5 . Cell lysates were prepared from ScN2a cells transiently transfected with WTPrP C and treated with PK or left untreated prior to Western blot analysis. The 3F4-positive signals in PK-treated extracts demonstrated the conversion of transfected WTPrP C (Fig. 5A ). Similarly, PrP(AV3) was converted into PrP Sc upon expression in ScN2a cells (Fig. 5A) . The cysteine variants of WTPrP C and PrP(AV3) were also expressed in ScN2a cells after transient transfection, illustrated by the 3F4-positive signals in lysates that have not been treated with PK prior to Western blot analysis (Fig. 5A, ϪPK) . However, after PK treatment of the lysates, almost no transfected PrP constructs converted into PrP Sc were detectable (Fig. 5A, ϩPK) . Quantification of PrP conversion rates confirmed that less than 1.5% of the transfected cysteine variants had been converted into PrP Sc (Fig. 5B) . Interestingly, the monomeric fraction of the cysteine variants, which is around 40% (Fig. 1, C and D) , was obviously also protected against conversion into prions. To investigate this phenomenon in more detail, we analyzed a possible effect of the forced PrP C dimers on the conversion of endogenous mouse PrP C , which lacks the Ser-to-Cys mutation. This approach allows to test whether the Cys point mutation itself and not the dimerization inhibits conversion by PrP Sc . Using the anti-PrP antibody 4H11, which detects both endogenous mouse and the transfected 3F4-positive PrP C /PrP Sc , we could show a significant reduction in the total amount of PK-resistant PrP Sc in cells expressing the cysteine variant of PrP (Fig. 5, C and D) . A similar dominant-negative effect on the conversion of WTPrP C was described earlier for certain deletion mutants of PrP (30) Importantly, expressing the serine variant of PrP(AV3) had no significant inhibitory effect on endogenous PrP Sc propagation, indicating that the decrease in endogenous PrP
Sc levels are not due to the transfection and/or expression of a mutated PrP. Please note that one cannot expect a similar decrease in the amount of endogenous mouse PrP Sc as seen for the transfected 3F4-positive PrP (Fig. 5, A and B) because ScN2a cells had already accumulated PrP Sc prior to the expression of the PrP C dimers, and PrP Sc has a half-life time Ͼ24 h. As another control, we generate an alanine variant of PrP C (PrP-A132). After transient expression in ScN2a cells, it was converted into PK-resistant PrP Sc , indicating that the mutation of the serine residue does not prevent conversion into PrP Sc (Fig. S1 ). In conclusion, the experiments in ScN2a cells revealed that dimeric PrP C is not converted into PrP Sc and has a dominant-negative effect on PrP Sc propagation in trans.
Discussion
Dimerization of cell surface receptors is often associated with their physiological function. Our study emphasizes a propensity of the cellular prion protein to form dimers at the plasma membrane. Furthermore, we show that neurotoxic mutations within the hydrophobic domain do not interfere with the formation of homodimers or heterodimers between mutant PrP and WTPrP C . However, in contrast to monomeric PrP, covalently linked PrP dimers are not converted into PrP Sc in scrapie-infected neuroblastoma (ScN2a) cells and inhibit prion propagation in trans.
The biological function of PrP C still remains enigmatic, but various studies suggest a role of PrP C as a cell surface receptor in stress-protective and neurotoxic signaling pathways (19, (31) (32) (33) (34) (35) (36) . Because receptors often form dimers, it is interesting to note that dimerization of PrP C has been described in vitro and in vivo (17) (18) (19) (20) . Using disulfide bridge-mediated dimerization, we first corroborated these studies and showed that covalently linked dimers of PrP are complex glycosylated and GPI-an- A, schematic presentation of the constructs analyzed. Straight line, intrinsically disordered regions; box, highly conserved HD; arrows, ␤-strands (␤). ␣-Helical structure is indicated by helices, polygons represent N-linked glycosylation acceptor sites, and GPI indicates the GPI anchor. The amino acid sequences of the HD of WTPrP C and PrP(AV3) are shown in the detail magnification. In some constructs, serine 132 is replaced by cysteine (denoted C132) to allow formation of an intermolecular disulfide bond. Numbering of the amino acids refers to human prion protein. B, scheme of the experimental strategy. In case PrP-C132 forms an intermolecular disulfide bond, PrP dimers can be separated from PrP monomers on SDS-PAGE under oxidizing conditions (ϪME). Under reducing conditions (Laemmli sample buffer containing ME), only PrP monomers are detected by Western blotting (ϩME). C, PrP forms disulfide bond-stabilized homodimers in neuronal cells. N2a cells were transiently transfected with WTPrP or PrP(AV3) containing a serine (S132) or cysteine (C132) at amino acid 132. Cell lysates were prepared and denatured by boiling in Laemmli sample buffer with (ϩME) or without reducing agent (ϪME). 
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chored to the outer leaflet of the plasma membrane. The introduction of an artificial disulfide bond allowed us to study a possible impact of dimerization on PrP maturation in the secretory pathway and to compare dimer formation between WT and mutant PrP. Specifically, these approaches revealed that at least 60% of total PrP dimerizes. Moreover, maturation and cellular trafficking of covalently linked PrP dimers were not altered compared with WTPrP C . Thus, neither the quality control machinery nor the glycan-modifying enzymes in the secretory pathway regarded PrP dimers as nonphysiological conformers. Finally, native immunoprecipitation assays provided evidence for the formation of WTPrP C dimers under physiological conditions. We observed that three mutations within the HD that induce the formation of neurotoxic PrP conformers (AV3) did not interfere with PrP dimerization, suggesting that the toxic potential of PrP(AV3) is not linked to alterations in dimer formation. However, we only analyzed dimer formation of the secreted form of PrP(AV3) and not of its transmembrane isoform, denoted PrP Ctm (22) . Our finding that PrP(AV3) interacts and forms stable heterodimers with WTPrP C might be relevant for the observation that WTPrP C can prevent the toxic activity of PrP mutants lacking the HD (PrP⌬HD) (37) . It is conceivable that WTPrP C via a direct interaction either blocks aberrant binding of PrP⌬HD to cellular proteins or prevents formation of a channel-forming PrP⌬HD conformer (38) .
One of the most important findings of our study was the resistance of forced PrP C dimers to be converted into PrP Sc and their activity to interfere with endogenous PrP Sc propagation in trans. After transient expression in ScN2a cells, WTPrP C as well as PrP(AV3) was converted into PK-resistant PrP Sc . The dimeric variants of both proteins were expressed; however, they were not converted into PrP Sc . Moreover, the PrP C dimers inhibited the conversion of the monomeric fraction of the transfected PrP constructs and of endogenous mouse PrP C in trans. It was reported previously that a secreted artificial PrPimmunoglobulin Fc (PrP-Fc 2 ) fusion protein that forms disulfide bond-stabilized dimers was not converted into PrP Sc and delayed onset of prion disease in transgenic mice (39 Sc is different and not suited to initiate or complete conversion. Because we artificially introduced a covalent linkage to stabilize PrP C dimers, one cannot rule out that this modification and not dimerization of PrP C blocked the conversion. In particular, the artificial cross-link could limit the structural mobility of the protein in ways that a native dimer may not, resulting in the inhibition of prion conversion. (iii) PrP C dimers bind to PrP Sc with a higher affinity than monomeric PrP C . As a consequence, interaction of monomeric PrP C with PrP Sc is decreased, and its conversion is reduced. (iv) PrP Sc in complex with PrP C dimers is subjected to increased intracellular degradation. It will now be interesting to explore the therapeutic potential of substances that can stabilize native PrP C dimers and hence block the conversion process.
Experimental procedures
Plasmids
Plasmid amplification and maintenance were carried out in Escherichia coli TOP10 (Thermo Fisher Scientific). The murine prion protein (GenBank TM accession number M18070) was modified to express PrP-L108M/V111M (40) , allowing detection by the mAb 3F4 (29) . The amino acid numbers refer to the human prion protein. All constructs generated for this study were developed by standard PCR cloning techniques. In some constructs, serine 132 was mutated to alanine or cysteine to enable the formation of a disulfide-bonded dimer (denoted A132 or C132). PrP(AV3) (A113V/A115V/A118V) was cloned 
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from a plasmid encoding PrP(AV3,L9R) kindly provided by David Harris (41). All constructs described above were inserted into pcDNA3.1/Neo (ϩ) vector (Invitrogen). If indicated, PrP mutants were equipped with a V5 tag (GGTAAACCGATACCG-AACCCGCTCCTCGGTCTCGATTCGACG) or HA tag (TAC-CCATACGATGTTCCAGATTACGCT) inserted in the unstructured N-terminal region between amino acids 35 and 36.
Antibodies and reagents
The following antibodies were used: anti-PrP monoclonal antibodies 3F4 (29) and 4H11 (42), mouse monoclonal anti-V5 antibody (mAb R960CUS, Thermo Fisher Scientific), anti-HA (mAb MMS-101R, Covance), mouse monoclonal anti-GAPDH (mAb AM4300, Thermo Fisher Scientific), horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (Thermo Fisher Scientific), and IRDye-conjugated secondary antibody (IRDye 800CW donkey anti-mouse, LI-COR Biosciences). All standard chemicals and reagents were purchased from Sigma-Aldrich if not otherwise noted. The following reagents were used: EndoH (New England Biolabs), PNGaseF (New England Biolabs), PIPLC (Thermo Fisher Scientific), trypsin (Thermo Fisher Scientific), monoclonal anti-HA-agarose beads (Sigma-Aldrich), cOmplete Mini EDTA-free Protease Inhibitor Mixture (Roche Applied Science).
Cell lines, transfection, and lysis
Human HeLa cells were cultured in Dulbecco's modified Eagle's medium (DMEM) GlutaMAX (Thermo Fisher Scien- tific), and murine N2a cells were cultured in minimum essential medium (MEM; Thermo Fisher Scientific), both with the addition of 10% fetal calf serum, 100 units/ml penicillin, and 100 g/ml streptomycin. Cells were grown in a humidified 5% CO 2 atmosphere at 37°C. Cells cultivated on a 3.5-cm cell culture dish (Nunc, Roskilde, Denmark) were transfected with plasmid DNA by a liposome-mediated method using Lipofectamine LTX and PLUS TM reagent (Life Technologies) according to the manufacturer's instructions. After 24 h, cells were washed twice with cold phosphate-buffered saline (PBS), scraped off the plate, pelleted by centrifugation (5,000 ϫ g, 5 min), and lysed in detergent buffer (0.5% Triton X-100, 0.5% sodium deoxycholate in PBS). The cell lysates were either analyzed directly or centrifuged (20, 000 ϫ g, 10 min ) to analyze the postnuclear supernatant.
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N2a cells persistently infected with the mouse prions strain 22L (22L-ScN2a) (28) were cultivated in Opti-MEM Gluta-MAX (Gibco). 22L-ScN2a cells were transfected using Lipofectamine LTX and PLUS TM reagent according to the manufacturer's protocol. Briefly, 1 ϫ 10 6 cells per plate were cultured in 10-cm plates. Plasmid (3 g) and PLUS TM reagent were incubated along with Opti-MEM medium for 5 min and then added to the mixture of Lipofectamine LTX reagent and Opti-MEM. The solution was kept for 15 min at room temperature. This solution was added drop by drop to cells and gently mixed. Cells were incubated at 37°C. After 48 h, a second transfection was done as described above. 96 h after the first transfection, cells were lysed in cold lysis buffer (10 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM EDTA, 0.5% Triton X-100, 0.5% sodium deoxycholate) for 10 min. One half of the lysate from each plate was incubated with PK at a final concentration of 20 g/ml for 30 min at 37°C. Proteinase inhibitor (0.5 mM Pefabloc) was added to inhibit PK digestion, and samples were precipitated in methanol. To the untreated sample, Pefabloc was added before methanol precipitation. Precipitated proteins were resuspended in TNE buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA).
Deglycosylation (PNGaseF and EndoH), phospholipase C treatment, and trypsin digestion
To deglycosylate proteins, cell lysates were treated with PNGaseF or endoglycosidase H for 1 h at 37°C according to the manufacturer's instructions. For PIPLC treatment, cells were washed twice with PBS. PIPLC diluted in PBS was added to the cells for 4 h at 37°C. Secreted PrP was precipitated by trichloroacetic acid (TCA) and analyzed by Western blotting. To analyze the localization of the prion protein and the generated mutants, cells were digested with trypsin, a member of the serine protease S1 family that digests cell surface proteins. Cells were washed twice with PBS and treated with trypsin for 25 min at room temperature. The reaction was terminated by the addition of cOmplete Mini EDTA-free Protease Inhibitor Mixture. Cell lysates were further analyzed by Western blotting.
Coimmunoprecipitation
To analyze formation of dimers, N2a or HeLa cells were cotransfected with the indicated constructs (V5-or HA-tagged) and lysed in detergent buffer (0.5% (v/v) Triton X-100, 0.5% (w/v) deoxycholate in PBS). Postnuclear supernatants were incubated with anti-HA-agarose beads under nonreducing conditions in the case of disulfide-stabilized coimmunoprecipitation and under reducing conditions for the native coimmunoprecipitation (overnight, 4°C, rotating). The immunocomplex was washed with lysis buffer and PBS and further analyzed by Western blotting.
Western blotting
For Western blot analysis, lysates were boiled in Laemmli sample buffer with or without ␤-mercaptoethanol (4%, v/v). Following SDS-PAGE, proteins were transferred to nitrocellulose by electroblotting. Membranes were blocked by incubation in TBS-T (TBS with 0.1% (w/v) Tween 20) containing 5% skimmed milk for 1 h at room temperature and incubated with primary antibody in TBS-T ϩ 5% skimmed milk for 18 h at 4°C. After washing with TBS-T, blots were incubated with respective secondary antibody (IRDye-IR Technology, LI-COR Biosciences; or HRP) in TBS-T for 1 h at room temperature. Protein signals were visualized using an Odyssey 9120 scanner. Peroxidase activity was detected by enhanced chemiluminescence (ECL) (Promega) .
To analyze PrP in persistently scrapie-infected 22L-ScN2a cells, Western blot analysis was performed as described previously (43) . Briefly, samples (ϮPK) were subjected to 12.5% SDS-PAGE and electroblotted on Hybond P 0.45-m PVDF membranes (Amersham Biosciences). Anti-PrP mAb 3F4 or 4H11 was used as primary antibody, and goat anti-mouse HRP antibody was used as secondary antibody. The detection of signal in the immunoblot was done using Luminata Western chemiluminescent HRP substrate (Millipore).
Quantification
Dimerization efficiency of the constructs was measured densitometrically (Image Studio Lite) as the percentage of dimer fraction relative to total protein amount. In ScN2a cells, the amount of total PrP and PrP Sc was also measured densitometrically (ImageJ software), and the relative amount of PrP Sc present in cells expressing WTPrP C was set as 1. Data represent mean Ϯ S.D. of Ն3 independent experiments. The standard deviation was determined using a Student's t test (*, p Ͻ 0.05; ns, not significant).
Immunofluorescence analysis
Transiently transfected HeLa cells were grown on glass coverslips and fixed 24 h after transfection with 4% paraformaldehyde (10 min). One set was permeabilized (0.2% Triton in PBS), and one set was left unpermeabilized. Both sets were blocked in PBS with 5% normal goat serum for 1 h and incubated with anti-3F4 antibody overnight at 4°C (in PBS containing 5% normal goat serum). After washing with PBS, incubation with the Cy3-conjugated anti-mouse secondary antibody (Alexa Fluor 488) followed for 1 h. Cells were mounted onto glass slides (with Fluoromount-G, Thermo Fisher Scientific) and examined by fluorescence microscopy (Zeiss ELYRA PS.1 and LSM 880).
